Zeneo® SQ – Subcutaneous, Zeneo® IM – Intramuscular and Zeneo® ID – Intradermal

Zeneo is a needle-free, pre-filled, single use device for intradermal, subcutaneous and intramuscluar injections.

Zeneo:

• Uses a single technological platform
• Drug volume range: 0.1–0.6ml
• User-friendly not syringe-like design
• Clinically proven well-established technology
• Adaptable to product viscosity

Other product developments:

• Intravitreal injections
• Larger volumes in Zeneo (up to 1 ml)/li>
• Injection of powders (patented)/li>

Intravitreal injection developments

• Design adapted to eye; very small injection volumes
• Preliminary testing on animals
• For retinopathies (diabetes, macular degeneration…)
• Eliminates infection risk to patient

No needle-stick injury

• High exposure: 12 billion injections/year worldwide
• Two million infections in 35 million Health Care Workers annually
• 800,000 needle-stick injuries are reported in the US each year, inducing an average cost of $1000 per injury (excl. contamination)
• Safety devices for the injections mandated in the US
• Through use of needles, unsafe injections cause millions infections per year in particular:
  Hepatitis B
  Hepatitis C
  HIV

No needle phobia

• Needle phobia is a defined condition that affects more than 10% (7%-22%) of the general population
• More than 15 million American adults and 5 million children suffer from high discomfort with injections
• Needle phobia leads to avoidance which may have severe medical consequences including death

Accuracy of dosing

• Compliance assured (if the injection is made…)
• Shorter duration of pain and user-friendly device improve prospects of injections being made
• Important regulatory benefit – safer, more likely to be effective
• Many classical syringe injections are thought to be inappropriate dose and/or injected at the wrong depth
• ID particularly difficult to achieve correctly with needles